Phase I Study of AK1940 in Healthy Japanese Subjects and Healthy Caucasian Subjects (Single Dose and Multiple Dose Study)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071250141

Enrollment

Registered

2026-03-16

Start date

2026-04-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteer

Interventions

Single or repeated subcutaneous administration of AK1940 or placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Japanese healthy men and women or Caucasian healthy men - Individuals >=18 to <45 years of age at the time of informed consent - Individuals who fully understand the details of the study and who are capable of providing written informed consent

Exclusion criteria

Exclusion criteria: - Subjects with clinical abnormalities in laboratory tests, vital signs, or fixed 12-lead electrocardiogram (ECG) - Subjects under 50.0 kg in men, less than 45.0 kg in women (in some parts: less than 50.0 kg) - Subjects with a BM of 1 (Japanese men: less than 18.5 kg/m2 or greater than 25.0 kg/m2; Japanese women: less than 17.5 kg/m2 or greater than 25.0 kg/m2; Caucasian: less than 18.5 kg/m2 or greater than 30.0 kg/m2)

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic endpoints: Pharmacokinetic parameters Safety endpoints: Adverse events, vital signs, clinical tests, ECG test	—

Contacts

Public ContactContact for Clinical Trial Information

ASAHI KASEI THERAPEUTICS CORPORATION

ct-info@om.asahi-kasei.co.jp+81-3-6699-3600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026